ReviewCurrent hypertension reports2013
Opportunities for targeting the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor pathway in hypertension.
Review in Current hypertension reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 62 citations in OpenAlex.
- Cross-Section of Hypertensive Molecular Signaling Pathways: Understanding Pathogenesis and Identifying Improved Drug Targets.Current hypertension reviews · 2025Review
- Gut Microbiota Perturbation in Early Life Could Influence Pediatric Blood Pressure Regulation in a Sex-Dependent Manner in Juvenile Rats.Nutrients · 2023Article
- Diet-gene interaction: effects of polymorphisms in the ACE, AGT and BDKRB2 genes and the consumption of sodium, potassium, calcium, and magnesium on blood pressure of normotensive adult individuals.Molecular and cellular biochemistry · 2021Article
- Targeting Angiotensin-Converting Enzyme-2/Angiotensin-(1-7)/Mas Receptor Axis in the Vascular Progenitor Cells for Cardiovascular Diseases.Molecular pharmacology · 2021Review
- Probing the Scope and Mechanisms of Calcitriol Actions Using Genetically Modified Mouse Models.JBMR plus · 2021Article
- Secreted Monocyte miR-27a, via Mesenteric Arterial Mas Receptor-eNOS Pathway, Causes Hypertension.American journal of hypertension · 2020Article
- ATPflugers Archiv : European journal of physiology · 2019Article
- Dynamic Variation of RAS on Silicotic Fibrosis Pathogenesis in Rats.Current medical science · 2019Article
- Connexin37-Dependent Mechanisms Selectively Contribute to Modulate Angiotensin II -Mediated Hypertension.Journal of the American Heart Association · 2019Article
- The roles of FGF21 in atherosclerosis pathogenesis.Reviews in endocrine & metabolic disorders · 2019Review
- Novel Medical Treatments for Hypertension and Related Comorbidities.Current hypertension reports · 2018Review
- Paracrine and Intracrine Angiotensin 1-7/Mas Receptor Axis in the Substantia Nigra of Rodents, Monkeys, and Humans.Molecular neurobiology · 2018Article
- Angiotensin-(1-7) and Alamandine on Experimental Models of Hypertension and Atherosclerosis.Current hypertension reports · 2018Review
- Cellular basis of angiotensin-(1-7)-induced augmentation of left ventricular functional performance in heart failure.International journal of cardiology · 2017Article
- The Angiotensin-(1-7)/Mas Axis Counteracts Angiotensin II-Dependent and -Independent Pro-inflammatory Signaling in Human Vascular Smooth Muscle Cells.Frontiers in pharmacology · 2016Article
- Aliskiren Administration during Early Postnatal Life Sex-Specifically Alleviates Hypertension Programmed by Maternal High Fructose Consumption.Frontiers in physiology · 2016Article
- Diminazene enhances stability of atherosclerotic plaques in ApoE-deficient mice.Vascular pharmacology · 2015Article
- Increased expression of angiotensin II type 2 receptors in the solitary-vagal complex blunts renovascular hypertension.Hypertension (Dallas, Tex. : 1979) · 2014Article
- Renin-angiotensin system in the kidney: What is new?World journal of nephrology · 2014Review
- Endothelium-dependent relaxation and angiotensin II sensitivity in experimental preeclampsia.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well known that the renin-angiotensin system (RAS) plays a pivotal role in the pathophysiology of cardiovascular diseases. This is well illustrated by the great success of ACE inhibitors and angiotensin (Ang) II AT(1) blockers in the treatment of hypertension and its complications. In the past decade, the classical concept of RAS orchestrated by a series of enzymatic reactions culminating in the linear generation and action of Ang II has expanded and become more complex. From the discoveries of new components such as the angiotensin converting enzyme 2 and the receptor Mas emerged a novel concept of dual opposite branches of the RAS: one vasoconstrictor and pro-hypertensive composed of ACE/Ang II/AT1; and other vasodilator and anti-hypertensive composed of ACE2/Ang-(1-7)/Mas. In this review we will discuss recent findings concerning the biological role of the ACE2/Ang-(1-7)/Mas arm in the cardiovascular system and highlight the initiatives to develop potential therapeutic strategies based on this axis for treating hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.